The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation

Introduction. The vast majority of patients with primary myelofibrosis (PMF) have been shown to carry driver mutations of JAK2, CALR (calreticulin gene) or MPL ì, and these molecular leasions may impact the clinical course of the disease. In a recent paper (Blood 2014;124:1062) patients with CALR mutation, had a lower risk of developing anemia, thrombocytopenia, marked leukocytosis, thrombosis and showed better overall survival, than either JAK2 -mutant or triple-negative patients.